The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression

Journal of Hematology & Oncology

B Hilda Ye²  Ru Feng¹  Xiangzhao Li³  Tong Zhao³  Fen Huang¹  Yongqiang Wei¹  Meng Xu¹  Xiaolei Wei¹ 

[1] Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China;Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA;Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China

关键词: Bone marrow involvement;    CD44 variant isoforms;    Rituximab;    CHOP;    Prognosis;    DLBCL;   

Others  :  801333
DOI  :  10.1186/1756-8722-7-34

 received in 2014-02-21, accepted in 2014-03-24,  发布年份 2014

【 摘 要 】

Expression of CD44 splice isoforms has been previously reported to correlate with inferior outcomes in DLBCL patients treated with CHOP therapy. However, it is unclear whether this observation remains valid in the R-CHOP era. In this study, we correlated CD44H and CD44v6 status with survival outcomes among DLBCL patients with an emphasis on the comparison between CHOP- and R-CHOP-treated subgroups. Our results suggest that rituximab has significantly decreased the prognostic value of CD44H. We also observed that the therapeutic benefit of rituximab is largely restricted to CD44H-positive cases in this cohort.

【 授权许可】

   
2014 Wei et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(4):235-242.
• [2]Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol: Official J Am Soc Clin Oncol 2006, 24(19):3121-3127.
• [3]Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9(2):105-116.
• [4]Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7(5):379-391.
• [5]Cang S, Mukhi N, Wang K, Liu D: Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012, 5:64. BioMed Central Full Text
• [6]Sehn LH: Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012, 2012:402-409.
• [7]Ponta H, Sherman L, Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4(1):33-45.
• [8]Guo W, Frenette PS: Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 2013.
• [9]Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST: Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990, 4(8):595-599.
• [10]Inagaki H, Banno S, Wakita A, Ueda R, Eimoto T: Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 1999, 12(5):546-552.
• [11]Drillenburg P, Wielenga VJ, Kramer MH, van Krieken JH, Kluin-Nelemans HC, Hermans J, Heisterkamp S, Noordijk EM, Kluin PM, Pals ST: CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia 1999, 13(9):1448-1455.